KZIA (KZIA) Stock Price & Analysis
KZIA (KZIA) rose 0.18% to USD 11.42 as of June 10, 2026 at 05:54 UTC, according to Nexqual real-time market data.
KZIA last closed at USD 11.4; the session ranged USD 10.87–11.87 on volume of 81,742 shares. Market capitalization is $130.50M, with a 52-week range of USD 4.86–17.4 (NCM). Source: Nexqual, June 10, 2026 at 05:54 UTC.
Key Statistics (as of June 10, 2026 at 05:54 UTC)
| Price | USD 11.42 |
|---|---|
| Change | ▲ 0.18% (up) |
| Previous Close | USD 11.4 |
| Open | USD 11.87 |
| Day Range | USD 10.87 – 11.87 |
| 52-Week Range | USD 4.86 – 17.4 |
| Volume | 81,742 shares |
| Market Cap | $130.50M |
| Exchange | NCM |
Technical Analysis (KZIA)
Nexqual's technical model rates KZIA "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:54 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.79 (neutral) |
| vs SMA50 | Below (USD 11.43) |
| MACD | -0.16 (negative) |
Analyst Ratings (KZIA)
Wall Street analysts rate KZIA "Buy" based on 3 analysts, with a mean price target of USD 23.86 (range USD 17.58–29.49), per Nexqual as of June 10, 2026 at 05:54 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 23.86 |
| High Target | USD 29.49 |
| Low Target | USD 17.58 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (KZIA)
Source: Nexqual, June 10, 2026 at 05:54 UTC.
Financials & Fundamentals (KZIA)
| Total Revenue | $1.90M |
|---|---|
| Revenue Growth (YoY) | +312.40% |
| Gross Margin | +100.00% |
| Operating Margin | -14641.04% |
| Profit Margin | +0.00% |
| ROE | -106.90% |
| Debt / Equity | 0.21 |
| Current Ratio | 2.87 |
| Total Cash | $69.46M |
| Total Debt | $98,807 |
| Free Cash Flow | $1.10M |
Source: Nexqual, June 10, 2026 at 05:54 UTC.
Financial Health Score (KZIA)
Nexqual rates KZIA's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 05:54 UTC.
| Growth | Strong — Revenue +312% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $69M cash, no debt |
| Cash Flow | Strong — FCF $1M, 58% margin |
| Efficiency | Critical — ROE -107%, ROA -25.7% |
Ownership (KZIA)
| Insider Ownership | +19.81% |
|---|---|
| Institutional Ownership | +28.81% |
| Shares Outstanding | 11.43M |
| Float | 8.04M |
| Short % of Float | +4.67% |
Source: Nexqual, June 10, 2026 at 05:54 UTC.
Leadership (KZIA)
KZIA is led by John Edwin Friend II (age 55), Chief Executive Officer, per Nexqual as of June 10, 2026 at 05:54 UTC.
| Chief Executive Officer | John Edwin Friend II (age 55) |
|---|---|
| Chief Financial Officer | James E. Levine (age 54) |
| Chief Scientific Officer | Sudha Rao |
Major Backers & Investors (KZIA)
Notable institutional backers of KZIA include Bleichroeder LP, Stonepine Capital Management, LLC, Point72 Asset Management, L.P., according to Nexqual as of June 10, 2026 at 05:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bleichroeder LP | 3.53% |
| Stonepine Capital Management, LLC | 3.04% |
| Point72 Asset Management, L.P. | 1.76% |
| Balyasny Asset Management LP | 1.7% |
| FLPutnam Investment Management Company | 1.26% |
| Velan Capital Investment Management LP | 1.19% |
| Dauntless Investment Group, LLC | 0.7% |
| Sequoia Financial Advisors, LLC | 0.53% |
Source: Nexqual, June 10, 2026 at 05:54 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| APVO | Aptevo Therapeutics Inc. | USD 4.76 | ▲ 0.85% |
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.11 | ▼ 2.63% |
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▲ 1.89% |
| IMRN | Immuron Limited | USD 1.19 | ▼ 4.8% |
| ATHE | Alterity Therapeutics Limited | USD 4.29 | ▲ 10% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:54 UTC. This page is informational and not investment advice.